Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

AgingUP: A Pilot Program to Reduce Self-Ageism and Self-Stigma in Older Adults With Severe Mental Illness (AgingUp)

1. Juli 2026 aktualisiert von: Macarena Sánchez-Izquierdo Alonso, Universidad Pontificia Comillas

AgingUP: A Pilot Psychosocial Program to Reduce Self-Ageism and Self-Stigma and Foster Positive and Realistic Views of Aging in Older Adults With Severe Mental Illness

The goal of this pilot clinical trial is to learn whether AgingUP, a 10-session psychosocial program, helps reduce self-ageism and self-stigma and fosters more positive and realistic views of aging in older adults (≥50 years) living with severe mental illness.

The main questions it aims to answer are:

  • Does participation in AgingUP reduce self-directed ageism compared to usual care?
  • Does it reduce internalized stigma related to mental illness?
  • Does it increase self-compassion?
  • Does it improve their perception of their own aging? Researchers will compare the AgingUP group with a control group receiving treatment as usual to see if participants in AgingUP show more adaptive perceptions of aging and self-concept.

Participants will:

  • Attend 10 weekly group sessions (60-75 min each) focused on cognitive-behavioral techniques, acceptance and commitment strategies, self-compassion exercises, and empowerment (as a transversal element).
  • Complete brief questionnaires about their experiences and attitudes before and after the program.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This research aims to generate preliminary evidence on the feasibility and potential effectiveness of AgingUP, a 10-session psychosocial program designed to reduce self-ageism and self-stigma and to foster more positive and realistic views of aging among older adults with severe mental illness (SMI). The program integrates Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), self-compassion training, positive narrative work, and social support.

The intervention is structured to progressively build cognitive, emotional, and social skills. The initial sessions provide psychoeducation and cognitive restructuring to help participants identify and challenge negative thoughts related to aging and mental illness. Mid-program sessions introduce values clarification and committed action from ACT, encouraging participants to act in alignment with personally meaningful goals. Later sessions focus on cultivating self-compassion and reconstructing positive life narratives that counter internalized stereotypes. The program concludes with a session on social connection and maintenance strategies.

AgingUP is implemented in group format within residential settings and compared to a control group receiving treatment as usual. Participants complete assessments at baseline and immediately after the 10-week intervention. The study will examine changes in self-directed ageism, self-stigma, self-compassion, symptoms, recovery and perception of successful aging.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

36

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Spanien
    • Madrid
      • Madrid, Madrid, Spanien, 28036
        • UNINPSI

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

Age: ≥ 50 years (preventive/therapeutic focus on early and late aging in Severe Mental Illness).

Diagnosis: Having a clinical diagnosis of Severe Mental Illness (SMI) such as schizophrenia, bipolar disorder, psychotic spectrum disorders, or severe affective disorders.

Active Treatment: Currently receiving psychiatric or psychosocial treatment in a mental health center, rehabilitation unit, or community service.

Legal Status: Not having a court-appointed legal representative. Voluntariness: Participation must be completely voluntary, without coercion or obligation.

Language and Communication: Able to communicate in the language used for the study/intervention (e.g., Spanish).

Availability: Willing to attend the scheduled sessions and activities according to the study/intervention design.

Exclusion Criteria:

  • Severe Cognitive Impairment: Presence of advanced dementia or severe neurodegenerative disease that limits understanding or informed consent.

Active Psychiatric Crisis: Experiencing an acute psychotic episode, manic crisis, or severe depression with high suicide risk at the time of assessment.

Severe Medical Conditions: Having medical illnesses that prevent participation in study activities.

Concurrent Study Participation: Participation in another ongoing study that may interfere with the objectives of this intervention.

Legal Incapacity: Having a legal incapacity that prevents free and voluntary participation.

Severe Cognitive Difficulties: Difficulties that significantly impair understanding of information or participation in group or digital activities.

Language Barrier: Inability to understand the language in which the intervention is conducted, limiting comprehension of study content.

Informed Consent: Failure to sign the informed consent form or expressing significant doubts about voluntary participation.

Lack of Availability: Unwillingness or inability to attend the sessions according to the structure and duration of the study.

Concurrent Participation: Participation in another study that could interfere with the goals of this intervention.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: AgingUP (Self-Ageism Reduction Program)
Participants receive the AgingUP program, a 10-session psychosocial group intervention combining CBT, ACT, self-compassion training, and positive narrative work, in addition to the treatment as usual provided at their center.
Verhalten: AgingUP (Self-Ageism Reduction Program)
AgingUP is a 10-session psychosocial group intervention combining Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), self-compassion training, and positive narrative work. Sessions focus on identifying and changing negative beliefs about aging and mental illness and on promoting more positive and realistic views of aging. It is delivered in addition to the treatment as usual provided at the participants' center.
Experimental: Waiting list
Participants continue with the treatment as usual provided at their center during the 10-week control period and are offered the AgingUP program afterward.
Verhalten: AgingUP (Self-Ageism Reduction Program)
AgingUP is a 10-session psychosocial group intervention combining Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), self-compassion training, and positive narrative work. Sessions focus on identifying and changing negative beliefs about aging and mental illness and on promoting more positive and realistic views of aging. It is delivered in addition to the treatment as usual provided at the participants' center.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
WHO Self-Directed Ageism Scale (15-item)
Zeitfenster: Baseline, Week 10 (end of intervention)
The scale evaluates self-directed ageism, defined as internalized stereotypes, prejudice, and discrimination related to one's own age. It includes 15 items rated on a 6-point Likert-type scale (from strongly disagree to strongly agree). Higher scores indicate higher levels of self-ageism.
Baseline, Week 10 (end of intervention)
Internalized Stigma of Mental Illness Scale (ISMI-29)
Zeitfenster: Baseline, Week 10 (end of intervention)
The ISMI-29 evaluates self-stigma associated with mental illness. It comprises 29 items rated on a 4-point Likert scale (from strongly disagree to strongly agree). The scale assesses five domains: alienation, stereotype endorsement, discrimination experience, social withdrawal, and resistance to stigma. Higher scores indicate greater internalized stigma.
Baseline, Week 10 (end of intervention)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Self-Compassion Scale (SCS-12)
Zeitfenster: Baseline, Week 10 (end of intervention)
The scale evaluates self-compassion, defined as a kind, understanding, and mindful attitude toward oneself in times of suffering. It includes 12 items rated on a 5-point Likert-type scale (from almost never to almost always). Higher scores indicate greater self-compassion.
Baseline, Week 10 (end of intervention)
Perception of Aging
Zeitfenster: Baseline and Week 10 (end of intervention)
This measure assesses participants' subjective perception of aging through three items: (1) a 10-point scale of perceived successful aging, (2) a 5-point Likert item ("I am aging well"), and (3) self-reported perceived physical and mental age. Higher ratings indicate more positive perceptions of aging.
Baseline and Week 10 (end of intervention)

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recovery Assessment Scale (RAS-24)
Zeitfenster: Baseline and Week 10 (end of intervention)
The scale assesses personal recovery in individuals with mental illness. It contains 24 items scored on a 5-point Likert-type scale (from strongly disagree to strongly agree), evaluating five dimensions: personal confidence and hope, willingness to ask for help, goal and success orientation, reliance on others, and no domination by symptoms. Higher scores indicate a stronger sense of recovery.
Baseline and Week 10 (end of intervention)
Symptom Checklist-45 abbreviated version
Zeitfenster: Baseline and Week 10 (end of intervention)
This scale evaluates psychological symptoms using 45 items rated on a Likert-type scale from 0 to 4 (Not at all - Very much or extremely). It assesses 9 domains (Depression, Hostility, Interpersonal Sensitivity, Somatization, Anxiety, Psychoticism, Obsession-Compulsion, Phobic Anxiety, and Paranoid Ideation). Mean scores range from 0 to 4. A higher score indicates more intense symptoms.
Baseline and Week 10 (end of intervention)
Protocol adherence form
Zeitfenster: At the end of each session, weekly from Week 1 to Week 10
At the end of each session, the group therapists complete a 10-item inventory rating the fulfillment of the session's objectives on a 3-point Likert-type scale (0 = not achieved, 1 = partially achieved, 2 = fully achieved).
At the end of each session, weekly from Week 1 to Week 10
Participants' satisfaction was measured by the Client Satisfaction Questionnaire (CSQ-8, Larsen et al., 1979)
Zeitfenster: Week 10 (end of intervention)
The CSQ-8 is an 8-item measure assessing general satisfaction with the group on a 4-point Likert-type scale from 1 to 4 (very dissatisfied - very satisfied). Mean scores range from 1 to 4. Higher scores indicate higher satisfaction.
Week 10 (end of intervention)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Universidad Pontificia Comillas

Ermittler

  • Hauptermittler: Macarena Sánchez-Izquierdo, PhD, Universidad Pontificia Comillas

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. Oktober 2025

Primärer Abschluss (Tatsächlich)

17. Dezember 2025

Studienabschluss (Tatsächlich)

17. Dezember 2025

Studienanmeldedaten

Zuerst eingereicht

16. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. Juli 2026

Zuerst gepostet (Tatsächlich)

8. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

8. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

1. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • PHS-2024/PH-HUM-169

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Psychische Störung

Klinische Studien zur AgingUP (Self-Ageism Reduction Program)

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Uruguay

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren